China SXT Pharmaceuticals Inc. (SXTC)
NASDAQ: SXTCHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
SXTC stock chart
Technical analysisKey statistics
All statistics- Market cap
- $273.95K
- EPS (TTM)
- -$73,040.00
- Dividend yield
- None
- 52-week range
- 2.52 – 8,376,000.00
- Day range
- 2.63 – 2.76
- Volume / Avg
- 24.95K / 234.25K
- Beta
- —
- Shares outstanding
- 103.58K
52-week range
SXTC stock today
On Nov 20, SXTC ended the session at $2.65, adding $0.055 (2.12%), versus the S&P 500's 3.70% decline. Trading was light, with 24.95K shares changing hands, about 11% of the average daily volume. At this level, SXTC sits near the bottom of its 52-week range of $2.52 to $8,376,000.00: 100.0% below the high and 4.9% above the low.
China SXT Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$73,040.00), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About China SXT Pharmaceuticals
Company profileChina SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers Advanced TCMP, including Directly-Oral-TCMP, and After-Soaking-Oral TCMP; Fine TCMP and Regular TCMP products; and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Feng Zhou
- Headquarters
- Taizhou
- Employees
- 56
- IPO year
- 2019
- Website
- sxtchina.com
Financial highlights
Full financialsIn fiscal 2026, China SXT Pharmaceuticals generated $1.1 million in revenue, down 34.6% from fiscal 2025, its first annual decline since 2025. China SXT Pharmaceuticals reported a net loss of $6.2 million, compared with a loss of $3.3 million a year earlier. Gross margin was 21.9% (up from 21.1%) and operating margin -625.9%.
| Fiscal year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Revenue | $1.14M | $1.74M | $1.93M | $1.97M | $2.60M |
| Growth | -34.63% | -9.73% | -2.19% | -24.23% | -45.53% |
| Net income | $-6.21M | $-3.30M | $-3.10M | $-5.93M | $-5.74M |
| EPS (diluted) | $-9.13 | $-348.17 | $-4,285.66 | $-177.84 | $-137.92 |
SXTC news
All SXTC newsChina SXT Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CDTCDT Equity Inc. | 0.23 | -13.89% | $437.03K | vs SXTC |
| SPRCSciSparc Ltd. | 0.1955 | -34.83% | $481.60K | vs SXTC |
| LSTALisata Therapeutics Inc. | 0.8989 | -1.22% | $647.45K | vs SXTC |
| OGENOragenics Inc. | 0.157 | -8.72% | $708.38K | vs SXTC |
| MTNBMatinas Biopharma Holdings Inc. | 0.7999 | -1.26% | $890.71K | vs SXTC |
| BDRXBiodexa Pharmaceuticals plc American Depositary Shs | 1.88 | -3.85% | $982.95K | vs SXTC |
| GOVXGeoVax Labs Inc. | 1.81 | -5.24% | $985.46K | vs SXTC |
| ARTLArtelo Biosciences Inc. | 1.39 | -4.14% | $1.30M | vs SXTC |
Indexes, lists and sector
China SXT Pharmaceuticals stock FAQ
What is China SXT Pharmaceuticals's stock price today?
SXTC last traded at $2.65 as of Nov 20, 4:00 PM EST, up 2.12% on the day. Prices are delayed at least 15 minutes.
Does China SXT Pharmaceuticals pay a dividend?
No. China SXT Pharmaceuticals does not currently pay a regular cash dividend.
Who is China SXT Pharmaceuticals's CEO?
Mr. Feng Zhou is the chief executive officer of China SXT Pharmaceuticals Inc., which has about 56 employees.
Has SXTC ever split its stock?
Yes. The most recent SXTC stock split was a 1-for-100 split on Oct 26, 2026.
What is the SXTC 52-week high?
The 52-week high for SXTC is $8,376,000.00 and the 52-week low is $2.52. The stock is currently 100.0% below its high.